search

Active clinical trials for "Dermatitis, Atopic"

Results 171-180 of 1075

A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory...

Atopic Dermatitis

Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of life after 16 and 24 weeks Change in sleep quality after 16 and 24 weeks Change in anxiety after 16 and 24 weeks Change in depression after 16 and 24 weeks Safety and tolerability

Recruiting5 enrollment criteria

The Effect of Intervention and Mechanism of ICBT on Chronic Itching in Patients With Atopic Dermatitis...

Atopic Dermatitis

Objectives: The study subjects were 180 healthy people from the dermatology clinic of Xiangya Hospital of Central South University and the surroundingcommunity, including 120 AD patients (60 in the ICBT treatment group and 60 in the control group) and 60 healthy controls. Methodology: After obtaining the informed consent of the subjects, the general condition and clinical symptoms of the subjects were assessed, the cognitive and psychological characteristics of the subjects who met the inclusion were assessed, multimodality MRI was scanned and blood and saliva samples were collected. The same assessments and data collection were performed with healthy controls matched for age, sex, and years of education in the AD patient group. AD patients were randomly assigned to the ICBT intervention group (n = 60) by a random number table and immediately started ICBT adjuvant therapy, or the control group (n = 60) for conventional therapy. Clinical symptoms and cognitive psychological characteristics of AD patients were assessed at the end of 2 weeks, 4 weeks, 8 weeks, 6 months and 12 months of ICBT treatment, and cognitive behavioral task measurements, multimodality magnetic resonance scans, blood and saliva samples will be performed again at the follow-up time point at the end of 6 months. Healthy controls (60) will also undergo a full set of follow-up assessments again after 6 months.

Not yet recruiting14 enrollment criteria

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of...

Atopic Dermatitis

The objective of the proposed study is to evaluate the tolerability and effectiveness of a 1% topical ointment of tofacitinib for the treatment of mild to moderate atopic dermatitis in adults. Adult patients with a diagnosis of atopic dermatitis for at least 6 months will be treated with the test product or placebo for a period of 8 weeks with a follow-up visit at 12 weeks. The primary endpoints are safety and tolerability of CGB-500 Ointment and a comparison of effectiveness of CGB-500 Ointment and Vehicle Ointments in treating lesion(s) of mild to moderate atopic dermatitis.

Not yet recruiting31 enrollment criteria

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With...

Dermatitis Atopic

This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) in approximately 48 pediatric participants (aged ≥6 and <14 years at study entry) with moderate-to-severe AD. After the 104-week treatment phase and the last assessment at the EndofTreatment (EOT) visit (as planned at Week 104), participants will be followed-up for 4 weeks and an End-of-Study (EoS) by telephone at 4 weeks after the EOT visit will end the study for each participant. The maximum duration of the study per participant will be 112 weeks (including screening period). TEWL assessment in predefined lesional and non-lesional skin areas before and after STS will be conducted every 3 months (every 13 weeks) during the treatment period from Day 1 (Baseline/Week 0, Visit 2) to Week 104 (Visit 10/EoT).

Not yet recruiting24 enrollment criteria

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection...

Atopic Dermatitis

The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

Not yet recruiting22 enrollment criteria

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Atopic DermatitisAtopic Dermatitis Eczema1 more

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

Not yet recruiting17 enrollment criteria

Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy...

Atopic DermatitisFood Allergy2 more

The aim of the study is to assess the prevalence of peanut, tree nuts, and sesame allergy in Polish children at high risk of food allergy. Additionally, the timing of the development of peanut, tree nuts and sesame allergy in the first three years of life in a high-risk population will be assessed.

Recruiting10 enrollment criteria

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

DermatitisAtopic

The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic immuno-modulatory therapies in Spanish daily practice. The main objectives are: To assess short and long-term safety of systemic therapies (including phototherapy) for atopic eczema (pharmacovigilance). To assess short and long-term effectiveness of systemic therapies, providing a basis for shared decision making and guidelines. Secondary objectives are: To assess short and long-term safety of topical therapies for atopic eczema. To assess effectiveness of different methods of care, including patient training. To describe atopic dermatitis comorbidities.

Recruiting6 enrollment criteria

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 3-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, SAR444656 dose 2 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by severity of AD (moderate [baseline EASI score <22] versus severe [baseline EASI score ≥22]). The total duration of study is approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.

Not yet recruiting24 enrollment criteria

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Atopic Dermatitis

The purpose of this study is to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.

Not yet recruiting10 enrollment criteria
1...171819...108

Need Help? Contact our team!


We'll reach out to this number within 24 hrs